---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058615"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:19:44.588442+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health Q1 net loss $3.3M; cash $121.4M; Remain-1 pivotal study H2 2024

## Summary
- Net loss $3.3M vs $11.9M YoY; includes $17.1M non-cash gain from fair value changes.
- Cash and cash equivalents $121.4M as of March 31, 2024; expected to fund operations through 2025.
- Expects to initiate Remain-1 pivotal study for weight maintenance after GLP-1 discontinuation in H2 2024.
- Topline data from Revitalize-1 pivotal T2D study anticipated in Q4 2024; enrollment completion expected Q2 2024.
- Appointed Adrian Kimber as Chief Commercial Officer; Germany registry study shows HbA1c reduction >1% and weight loss >15 lbs at 3 months.

## SEC filing metadata
- accession: 0000950170-24-058615
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000095017024058615/0000950170-24-058615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000095017024058615/guts-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058615
- JSON: https://secwatch.observer/filing/0000950170-24-058615.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058615.txt

## Key facts
- Earnings Releases
  FRACTYL HEALTH, INC. reported first quarter 2024 results: revenue Revenue in the quarter ended March 31, 2024.
  - Period: first quarter 2024
  - Revenue: Revenue in the quarter ended March 31, 2024
  - Result: reported results
  source text: Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today reported its first quarter 2024 financial results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1572616/000095017024058615/0000950170-24-058615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.